SDC1 and prostate carcinoma: Previously, we reported a larger prognostic TMA containing tissue samples of prostate cancers from 551 patients with long-term follow-up on progression, overall and tumor-specific survival and identified the prognostic significance of syndecan-1 in prostate cancer, as well as a downregulation of CD-10 after neoadjuvant hormonal therapy [13].